TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02602041

Intervention type: OTHER
Intervention: Literature search and semi-structured interview
Description: We will do a literature search and perform semi-structured interviews with cancer patients and their partners in order to explore knowledge, attitudes, barriers and facilitators regarding health behavior change following cancer treatment.

Intervention type: OTHER
Intervention: Literature search and semi-structured interview
Description: We will do a literature search and perform semi-structured interviews with cancer patients and their partners in order to explore knowledge, attitudes, barriers and facilitators regarding health behavior change following cancer treatment.
Study: NCT01312922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNB01 fixed dose combination of pipamperone and citalopram
Description: oral once daily administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: oral once daily administration

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Pipamperone
Description: oral once daily administration
Study: NCT03420300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBR/GZR
Description: Elbasvir/grazoprevir (EBR/GZR 50mg/100mg fixed dose combination \[FDC\]): 1 table per os per day for 12 weeks
Study: NCT00322465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinidazole
Description: 2 gm single dose (4 tablets orally at 500 mg each).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinidazole
Description: 2 gm single dose (4 tablets orally at 500 mg each).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule will be filled with lactose only and be identical in appearance to the capsule of Azithromycin, Tinidazole, Doxycycline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule will be filled with lactose only and be identical in appearance to the capsule of Azithromycin, Tinidazole, Doxycycline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule will be filled with lactose only and be identical in appearance to the capsule of Azithromycin, Tinidazole, Doxycycline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule will be filled with lactose only and be identical in appearance to the capsule of Azithromycin, Tinidazole, Doxycycline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 100 mg orally, twice daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 100 mg orally, twice daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 1 gram (gm) (2 tablets orally at 500 milligrams (mg) each).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 1 gram (gm) (2 tablets orally at 500 milligrams (mg) each).
Study: NCT03354104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The tunnel technique for root coverage with Emdogain
Description: The tunnel technique for root coverage with Emdogain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The tunnel technique for root coverage without Emdogain
Description: The tunnel technique for root coverage without Emdogain
Study: NCT05055349

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: corneal ring segments
Description: ring hard segments inserted within corneal stroma using femtolaser

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: corneal ring segments
Description: ring hard segments inserted within corneal stroma using femtolaser
Study: NCT04668105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High volume nordic hamstring exercise
Description: To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again.Group 1 will do the Nordic hamstring exercise with protocol 3 repetitions × 3sets× 3 times for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low volume nordic hamstring exercise
Description: To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again. Group 2 will do the Nordic hamstring exercise with protocol 3 repetitions × 3 sets × 1 times for 4 weeks.
Study: NCT01228409

Intervention type: DRUG
Group type: OTHER
Intervention: Acitretin 17.5 mg/day
Description: lower dose of Acitretin to 17.5 mg/day from 25 mg/day in those experiencing retinoid-related side effects
Study: NCT04043065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liver-enriched antimicrobial peptide 2
Description: Infusion of LEAP-2 during a 180 min grated glucose infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT00556127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 110 mg/m2 on day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1200 mg/m2 on day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 (maximum 2 mg) on day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m2 from day 1 to 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony-stimulating factor
Description: (G-CSF 5 μg/Kg/day) from day 5 to day 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 8 mg/m2 for 3-day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine ARA-C
Description: 2 g/m2/12 hours for six doses in 3-hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg/m2/12 hours before ARA-C administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine BCNU
Description: 300 mg/m2 on day -7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2/12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m2 on day -2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Involved Field Radiotherapy (IF-RT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC reinfusion
Description: ASCT
Study: NCT02423902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12
Description: Approximately 1.0x10\^12 viral particles (vp) per injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veledimex
Description: 7 oral doses of veledimex
Study: NCT00804661

Intervention type: DEVICE
Intervention: SENTEC device
Description: Nocturnal recording SAO2 and PtcCO2 and wrist movements by means of actigraphy
Study: NCT01075581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrin (Intranasal injection)
Description: A total of 8 mL of epinephrine 1:100,000 will be injected in the lateral nasal wall, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrin (Topical administration)
Description: An intranasal injection of saline solution, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
Study: NCT02270970

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: belimumab
Description: belimumab will be given at 10 mg/kg intravenously at Week 1, Week 2, Week 4 and monthly after that as was done in Phase III trials and approved in the FDA label

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: belimumab
Description: belimumab will be given at 10 mg/kg intravenously at Week 1, Week 2, Week 4 and monthly after that as was done in Phase III trials and approved in the FDA label
Study: NCT00048581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Vials, intravenous (IV), \~10mg/kg abatacept, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vials, IV, 0mg, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Vials, IV, \~10mg/kg abatacept, every 4 weeks, 5.5 years
Study: NCT03500692

Intervention type: DEVICE
Intervention: MitraClip NT System
Description: Percutaneous mitral valve repair using MitraClip NT System
Study: NCT01459328

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Short course radiotherapy: 25Gy in 5 daily fractions over 1 week Chemotherapy: - Bolus 5 Fluorouracil 450 mg/m2/day~* Injected Leucovorin 20 mg/m2/day for 5 days

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Conventional long course chemo-radiation:~* Radiation 50Gy in 25 daily fractions over 5 weeks~* Bolus 5 Fluorouracil 350mg/m2/d for 5 days~* Injected Leucovorin 20mg in both the first and last (5th) week of radiation~* Oral Capecitabine (CAPE) 825mg/m2 b.i.d. during the entire radiotherapy course over 5 weeks.
Study: NCT04666909

Intervention type: DIAGNOSTIC_TEST
Intervention: blood pressure
Description: The Welch Allyn ABPM 7100 is an easy-to-use 24-hour ambulatory blood pressure monitor that is designed to help avoid the effects of white coat hypertension, provide accurate sleep blood pressure readings, and tailor drug therapy regimes to your individual patient's needs.~This device is programmed to take three BP readings a minute apart. To be eligible, participants must have an average SBP \> 135 mm Hg or DBP \> 85 mmHg (based on the average of 3 BP readings); or average SBP \> 130 mm Hg or DBP \> 80 mm hg (for those with diabetes or kidney disease) based on JNC-7 criteria for uncontrolled HTN.
Study: NCT01279525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multifactorial
Description: individual advice, information leaflet, physical exercise workshop and home visits
Study: NCT02154321

Intervention type: DEVICE
Intervention: Electroencephalogram (EEG)
Description: The electroencephalogram assesses brain electrical activity through surface recording disks (electrodes) which are placed near the participants' head using a custom designed Lycra cap. The electrodes transmit the signals which are then amplified and stored on a computer. The procedure is entirely non-invasive. Once an accurate signal is assured, the signal derived from the electrode cap is then amplified, transmitted to a computer, and stored for later analysis. Each participant will undergo the electroencephalogram (EEG) procedure only once for the duration of 30-45 minutes.

Intervention type: DEVICE
Intervention: Electroencephalogram (EEG)
Description: The electroencephalogram assesses brain electrical activity through surface recording disks (electrodes) which are placed near the participants' head using a custom designed Lycra cap. The electrodes transmit the signals which are then amplified and stored on a computer. The procedure is entirely non-invasive. Once an accurate signal is assured, the signal derived from the electrode cap is then amplified, transmitted to a computer, and stored for later analysis. Each participant will undergo the electroencephalogram (EEG) procedure only once for the duration of 30-45 minutes.
Study: NCT02780570

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small Volume Plasma Exchange
Description: Six sessions will be done daily for consecutive 8 days (total 48 sessions). 7 ml/body weight blood will be drawn at each session and will be separated into plasma and blood cells. Blood cells will be infused back to the patients and plasma will replaced by equal volume of fresh frozen plasma and colloid solution. At the end of each day 1200 ml plasma (total 9600 ml in 48 sessions) will be removed.
Study: NCT03920137

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UP-ST Therapy
Description: Phase 1 analyses will focus primarily on demonstrating feasibility and utility of the new UP-ST intervention. Feasibility will be determined by examining the proportion of individuals who 1) complete each module of the UP-ST treatment, 2) complete a full course of the UP-ST treatment, and by 3) benchmarking participant ratings of treatment credibility, expectancy, and satisfaction with corresponding ratings from our previous clinical trials examining the UP or ST interventions. The investigators will include and examine outcomes on the same measures that will be used in phase 2, but due to the sample size our analyses for Phase 1 will focus on intraindividual effect sizes (with 95% CI) for continuous smoking, anxiety, and depression outcomes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Therapy
Description: In the control group therapists will hold standard smoking cessation therapy sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Nicotine patches will be worn in tandem with UP-ST therapy
Study: NCT02051309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: 6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. Follow up at 1 month, 2 months and 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03174756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypochlorous Acid
Description: Mouthwashes of antiplaque agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypochlorous Acid
Description: Mouthwashes of antiplaque agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water as placebo
Study: NCT03423225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAGRAF®
Description: Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~* Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~* Duration of treatment The investigational product will be administered for 24 weeks.
Study: NCT01371409

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: continuous theta burst stimulation
Description: 80% active motor threshold, 600 pulses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation
Description: 80% active motor threshold, 600 pulses
Study: NCT01234103

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits
Description: Groups will be randomly assigned to the sexual/substance use prevention intervention or the comparative/control intervention focused on impro risk Involves 10 hours of didactic presentations, interactive group discussions, skills-building exercises, and topic specific videos to reduce participants' risk for and acquisition of STIs, unintended pregnancies and their associated sexual and substance use behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits
Description: Groups will be randomly assigned to the sexual/substance use prevention intervention or the comparative/control intervention focused on impro risk Involves 10 hours of didactic presentations, interactive group discussions, skills-building exercises, and topic specific videos to reduce participants' risk for and acquisition of STIs, unintended pregnancies and their associated sexual and substance use behaviors.
Study: NCT00802100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Daily tablets of 10 to 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perphenazine
Description: Daily tablets of 8 to 24 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Daily tablets of 10 to 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Daily tablets of 850 to 2550 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Daily tablets of 850 to 2550 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Daily tablets of 850 to 2550 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Daily tablets of 20 to 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Daily tablets of 20 to 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Daily tablets of 20 to 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benztropine
Description: Daily tablets of 1 to 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benztropine
Description: Daily tablets of 1 to 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benztropine
Description: Daily tablets of 1 to 2 mg
Study: NCT03171155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XPro System
Description: Implantation of the XPro System
Study: NCT04112082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Neurofeedback
Description: Home-based neurofeedback training (downtrain theta, uptrain beta; training site: Cz) 4 times weekly for a 40 of total sessions over the ten-week training period. Session duration of 21 minutes for the first 20 sessions to 30 minutes for the last 20 sessions. Positive visual and auditory feedback when brainwaves are within the desired range.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment plan as part of regular care at the ADHD clinic, which may include pharmacological intervention, cognitive behavioral therapy (CBT), a combination of pharmacological intervention and CBT, or no intervention. Care will often include pharmacological intervention, with the specifics (e.g., type of medication, dosage) determined by psychiatrist recommendation considering such factors as response to previous interventions, participant characteristics, and practical constraints. Most pharmacological interventions will be stimulants (e.g., methylphenidate) with various release mechanisms. Each participant will receive an individualized dose titration and follow-up plan, including clinic visits as needed (generally 1-2 visits over the 10-week intervention period); interventions may be switched in accord with clinical judgment.
Study: NCT02613156

Intervention type: PROCEDURE
Intervention: laparoscopic resection
Description: The surgical instruments used for the laparoscopic group included conventional laparoscopic instruments (three 5 mm trocars, two 10 mm trocars, and two damage-free laparoscopic clamps), the STORZ high-resolution laparoscopic operating system (Germany), the GEN300 ultrasonic scalpel system (Johnson \& Johnson, USA), a laparoscopic linear cutter stapler (Johnson \& Johnson, USA), a laparoscopic ultrasound device, LigaSure, bipolar coagulation, titanium laparoscopic clips, and absorbable hemostatic gauze.
Study: NCT04137679

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Definitive Radiochemotherapy
Description: Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Definitive Radiochemotherapy
Description: Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Radiochemotherapy followed by surgery
Description: Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant Radiochemotherapy followed by surgery
Description: Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
Study: NCT02029105

Intervention type: BIOLOGICAL
Intervention: Mesothelin, hyaluronan, osteopontin, syndecan-1
Description: We compere the serum levels of the tumor markers in patients with pleural diseases according to the groups for the diagnosis and differential diagnosis of the diseases.
Study: NCT00912288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon 20 mg po TID
Description: Dimebon 10 mg po TID for 1 week followed by Dimebon 20 mg TID for 25 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo po TID
Description: Placebo (matched to Dimebon) po for 26 weeks
Study: NCT00611819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg interferon + Ribavirin
Description: Peg interferon 180 mcg/weekly Ribavirin 800 mg/daily during 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg interferon + Ribavirin
Description: Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks